Health care consequences of black-box warnings for antidepressants in the United States and Canada

Research in Social and Administrative Pharmacy

Volumn 6, Issue 1, 2010, Pages 78-84

  Nagar, Saurabh ^a   Mehta, Sandhya ^a   Bhatara, Vinod ^b   Aparasu, Rajender ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Anti depressive agents; Black box; Regulatory; Suicide; Warnings

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CANADA; CHILD; DRUG LABELING; DRUG LEGISLATION; FOOD AND DRUG ADMINISTRATION; HUMAN; UNITED STATES;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CANADA; CHILD; DRUG LABELING; HUMANS; LEGISLATION, DRUG; SEROTONIN UPTAKE INHIBITORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 76949095202     PISSN: 15517411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sapharm.2009.02.005     Document Type: Article

References (23)

1. Mark O., Steven M., and Benjamin D. Effects of food and drug administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry 65 1 (2008) 94-101
2. Harris G. FDA toughens warning on antidepressant drugs. Available at:. New York Times (October 2004). http://www.nytimes.com/2004/10/16/politics/16depress.html Accessed 20.01.09
3. Vedantam S. Depression drugs to carry warning: FDA orders notice of risks for youths. Washington Post; October 16, 2004:A01.
4. Brent D.A. Antidepressants and pediatric depression-the risk of doing nothing. N Engl J Med 351 16 (2004) 1598-1601
5. Newman T.B. A black-box warning for antidepressants in children?. N Engl J Med 351 16 (2004) 1595-1598
6. FDA. FDA Public Health Advisory: Report of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). Available at: (October 27, 2003). http://www.fda.gov/CDER/drug/advisory/mdd.htm US Food and Drug Administration website. Accessed 17.02.09
7. FDA. FDA Public Health Advisory: Sucidality in children and adolescents being treated with antidepressant medications. Available at: (October 15, 2004). http://www.fda.gov/CDER/DRUG/antidepressants/SSRIPHA200410.htm US Food and Drug Administration website. Accessed 17.02.09
8. FDA. FDA news: FDA launches a multi-prolonged strategy to strengthen safeguards for children treated with antidepressant medications. Available at: (May 2007). http://www.fda.gov/bbs/topics/news/2007/new01624.html US Food and Drug Administration website. Accessed 17.02.09
9. Hetrick S.E., Merry S.N., McKenzie J., et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews (2007) Issue 3
10. Whittington C.J., Kendall T., Fonagy P., et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363 9418 (2004) 1341-1345
11. Zito J.M., Safer D.J., Dosreis S., et al. Rising prevalence of antidepressants among US youths. Pediatrics 109 5 (2002) 721-727
12. Vitello B., Zuvekas S.H., Norquist G.S., et al. National estimates of antidepressant medication use among U.S. children, 1997-2002. J Am Academy Child Adolesc Psychiatry 45 3 (2006) 271-279
13. Ma J., Lee K.V., and Stafford R.S. Depression treatment during the outpatient visits by U.S. children and adolescents. J Adolesc Health 37 6 (2005) 434-442
14. Nemeroff C.B., Kalali A., Keller M.B., et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 64 4 (2007) 466-472
15. Libby A.M., Brent D.A., Morrato E.H., et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 164 6 (2007) 884-891
16. Valuck R.J., Libby A.M., Orton H.D., et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 164 8 (2007) 1198-1205
17. Gibbons R.D., Brown C.H., Hur K., et al. Early evidence on the effects of regulator's suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164 9 (2007) 1356-1363
18. Morrato E.H., Libby A.M., Orton D.H., et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 165 1 (2008) 42-50
19. Kurian B.T., Ray W.A., Arbogast P.G., et al. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pedatr Adolesc Med 161 7 (2007) 690-696
20. Katz L.Y., Kozyrskyj A.L., Prior H.J., et al. Effect of regulatory warnings on antidepressant prescription rates, use of healthcare services and outcomes among children, adolescent and young adults. CMAJ 178 8 (2008) 1005-1011
21. FDA. Labeling change request letter for antidepressant medications. Available at: (May 2007). http://www.fda.gov/CDER/DRUG/antidepressants/ssrilabelchange.htm US Food and Drug Administration website. Accessed 17.02.09
22. Lineberry T.W., Bostwick J.M., Beebe T.J., et al. Impact of the FDA black-box warnings on physician antidepressant prescribing and practice patterns: opening pandora's suicide box. Mayo Clin Proc 82 4 (2007) 516-522
23. Mann J.J., Emslie G., Baldessarini R.J., et al. ACNP Task force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 31 3 (2006) 473-492